← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV17행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
Lorvotuzumab Mertansine (Lorvotuzumab Mertansine)
ImmunoGen, Inc.·Pleuropulmonary Blastoma
7 trials
Overview
Program
Lorvotuzumab Mertansine
Overview
Company
ImmunoGen, Inc.
Overview
Modality
ANTIBODY
Overview
Target
Pleuropulmonary Blastoma
Overview
Indication
Pleuropulmonary Blastoma; Recurrent Malignant Peripheral Nerve Sheath Tumor
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.. Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate linking an antimitotic agent (DM1) to an anti-CD56 antibody (lor…
Clinical
Safety signal
ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncology Group study.. Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate linking an antimitotic agent (DM1) to an anti-CD56 antibody (lor…
Clinical
Reported ORR
0.00%
Clinical
Result source
ClinicalTrials.gov NCT02452554
Clinical
Program phase
PHASE_2
Clinical
Trial ref
NCT02452554
Lorvotuzumab Mertansine 비교 | 바이오정보모아